Abstract 309P
Background
Neratinib, an oral irreversible pan-HER tyrosine kinase inhibitor, was approved in 2020 in China. However, with the evolving treatment practices for HER2+ EBC in China, like the increased use of pertuzumab, understanding real-world extended adjuvant neratinib use in China is crucial.
Methods
This is a multi-center, prospective, non-interventional study planning to enroll 500 HER2+ EBC patients who scheduled extended adjuvant neratinib treatment. The primary and secondary objectives are to describe the real-world adjuvant treatment patterns and to observe the safety of patients treated with neratinib respectively.
Results
As of 21 September 2023, 250 patients were included in the analysis. 90.5% in the neoadjuvant therapy and 88% in the adjuvant therapy received pertuzumab plus trastuzumab. The median time from completion of previous adjuvant therapy until the start of neratinib treatment was 1.3 months (interquartile range: 0.69-3.38). The initial dose of neratinib was <240 mg for 51.2% and 240 mg for 48.8% of the patients. 59.6% received diarrhea prophylaxis at least once, including prophylaxis medication (33.2%), dose-escalated (17.2%), or both (9.2%). Serious adverse events (SAEs) and Grade ≥3 adverse events (AEs) were reported in 3.6% and 18.8% of the patients respectively. The most common AEs of any grade were diarrhea (79.6%), nausea (20.4%), and fatigue (14.8%). Diarrhea was predominantly reported as Grade 1 or 2 (64.8%), while Grade ≥3 diarrhea was reported in 14.8% of the patients. The incidence of Grade ≥3 diarrhea was lower in the patients starting neratinib at <240 mg (10.2%) as compared with 240 mg (19.7%).
Conclusions
The profile of patients and pattern of anti-HER2 pretreatment reflected the current disease and treatment landscape for HER2+ EBC in China. The overall safety profile was consistent with previously reported data. With cross-trial comparison, the proportion of patients with Grade ≥3 diarrhea was lower if indirectly compared to the ExteNET study (14.8% vs. 40%), which may reflect increasing awareness of the risk of diarrhea and increasing use of the antidiarrheal strategies.
Clinical trial identification
NCT05491057.
Editorial acknowledgement
Legal entity responsible for the study
Pierre Fabre.
Funding
This study is sponsored by Pierre Fabre.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
312P - Early detection of metastatic disease in asymptomatic early-stage breast cancer patients using imaging: A cross-sectional analytic study at a tertiary hospital
Presenter: John kelvin Lalusis
Session: Poster session 14
313P - A longitudinal follow-up study on the prognosis of patients with breast cancer with delayed diagnosis during the COVID-19 pandemic
Presenter: Jae Pak Yi
Session: Poster session 14
314P - The impact of changes in tumor mutational landscape during neoadjuvant therapy on tumor-informed ctDNA testing in breast cancer patients
Presenter: Mark Magbanua
Session: Poster session 14
315P - Long-term tamoxifen benefit in pre- and postmenopausal patients of high and low risk with luminal A and B breast cancer
Presenter: Oscar Danielsson
Session: Poster session 14
316P - Differential long-term benefit of 2-year adjuvant tamoxifen therapy for luminal-type breast cancer: Insights from a 20-year follow-up analysis of the STO trials
Presenter: Magdalena Rios Romero
Session: Poster session 14
317TiP - A randomized, multicenter, open-label phase II neoadjuvant study to evaluate the safety and efficacy of HER2-ADC disitamab vedotin in combination toripalimab or sequence chemotherapy in participants with HR-negative, HER2 low-expressing breast cancer
Presenter: Zhimin Shao
Session: Poster session 14
318TiP - Neoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in stage II-III HER2-positive breast cancer: The TRAIN-4 study
Presenter: Fleur Louis
Session: Poster session 14
319TiP - NeoBREASTIM: A phase II study of atezolizumab plus RP1 oncolytic immunotherapy in the neoadjuvant setting of triple-negative breast cancer (TNBC)
Presenter: Etienne Bastien
Session: Poster session 14
321P - Sentinel lymph node biopsy in clinical T3-4c breast cancer: A retrospective multicenter cohort study
Presenter: Yasuaki Sagara
Session: Poster session 14
322P - Incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010-2021
Presenter: Alexandra Thomas
Session: Poster session 14